Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Meric

Showing results (51-60 of 68) with videos related to

Pageof 7
Sort By:
Annals of Surgical Oncology|October 18, 2000
Ductal carcinoma-in-situ: long-term results of breast-conserving therapyN Q Mirza, G Vlastos, F Meric, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 6, 2016
Utility of a molecular prescreening program in advanced colorectal cancer for enrollment on biomarker-selected clinical trialsM J Overman, V Morris, B Kee, et al.
BMC Cancer|October 18, 2015
Retreatment with anti-EGFR based therapies in metastatic colorectal cancer: impact of intervening time interval and prior anti-EGFR responseX Liu, G C George, A M Tsimberidou, et al.
JCO Precision Oncology|September 14, 2019
Expanded analysis of secondary germline findings from matched tumor/normal sequencing identifies additional clinically significant mutationsE Ileana Dumbrava, L Brusco, M Daniels, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 4, 2019
Germline-focussed analysis of tumour-only sequencing: recommendations from the ESMO Precision Medicine Working GroupD Mandelker, M Donoghue, S Talukdar, et al.
ESMO Open|August 6, 2025
Autoantibody profiling to predict response to the anti-PD-1 therapy, pembrolizumab, in rare tumorsM H Derbala, J Hajjar, B Stephen, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 4, 2024
Recommendations for the use of next-generation sequencing (NGS) for patients with advanced cancer in 2024: a report from the ESMO Precision Medicine Working GroupM F Mosele, C B Westphalen, A Stenzinger, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 21, 2017
High prevalence of mutant KRAS in circulating exosome-derived DNA from early-stage pancreatic cancer patientsK Allenson, J Castillo, F A San Lucas, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 28, 2020
Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working GroupF Mosele, J Remon, J Mateo, et al.
ESMO Open|March 15, 2021
Safety and activity of vandetanib in combination with everolimus in patients with advanced solid tumors: a phase I studyT Cascone, R L Sacks, I M Subbiah, et al.
Pageof 7

Showing results (51-60 of 68) with videos related to

Sort By:
Pageof 7
Annals of Surgical Oncology|October 18, 2000
Ductal carcinoma-in-situ: long-term results of breast-conserving therapyN Q Mirza, G Vlastos, F Meric, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 6, 2016
Utility of a molecular prescreening program in advanced colorectal cancer for enrollment on biomarker-selected clinical trialsM J Overman, V Morris, B Kee, et al.
BMC Cancer|October 18, 2015
Retreatment with anti-EGFR based therapies in metastatic colorectal cancer: impact of intervening time interval and prior anti-EGFR responseX Liu, G C George, A M Tsimberidou, et al.
JCO Precision Oncology|September 14, 2019
Expanded analysis of secondary germline findings from matched tumor/normal sequencing identifies additional clinically significant mutationsE Ileana Dumbrava, L Brusco, M Daniels, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 4, 2019
Germline-focussed analysis of tumour-only sequencing: recommendations from the ESMO Precision Medicine Working GroupD Mandelker, M Donoghue, S Talukdar, et al.
ESMO Open|August 6, 2025
Autoantibody profiling to predict response to the anti-PD-1 therapy, pembrolizumab, in rare tumorsM H Derbala, J Hajjar, B Stephen, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 4, 2024
Recommendations for the use of next-generation sequencing (NGS) for patients with advanced cancer in 2024: a report from the ESMO Precision Medicine Working GroupM F Mosele, C B Westphalen, A Stenzinger, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 21, 2017
High prevalence of mutant KRAS in circulating exosome-derived DNA from early-stage pancreatic cancer patientsK Allenson, J Castillo, F A San Lucas, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 28, 2020
Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working GroupF Mosele, J Remon, J Mateo, et al.
ESMO Open|March 15, 2021
Safety and activity of vandetanib in combination with everolimus in patients with advanced solid tumors: a phase I studyT Cascone, R L Sacks, I M Subbiah, et al.
Pageof 7